Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

elbion and Wyeth team up on PDE10 inhibitors for CNS disorders

Feb. 8, 2007

Treatment completed in phase III trials of Miraxion in Huntington's disease

Feb. 7, 2007

Novel activation mechanism for the pain-sensing TRPA1 channel / News in Context

Feb. 7, 2007

NF-kappaB inhibitors inhibit Abeta production in vitro: potential efficacy in AD

Feb. 7, 2007

Blockade of the orexin OX1/OX2 receptors with ACT-078573 promotes sleep in rats, dogs and humans

Feb. 6, 2007

Shionogi and Lilly to codevelop and comarket duloxetine in Japan

Feb. 6, 2007

Neurochem completes North American phase III study of tramiprosate

Feb. 6, 2007

Methylphenidate to commence clinical trial for the treatment of cancer-related fatigue

Feb. 6, 2007

ND-0601 transdermal levodopa patch completes pilot study

Feb. 6, 2007

Simvastatin enhances cognition by Abeta-independent mechanism in mice

Feb. 5, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...